Characteristics of 146 study cases
| Characteristic . | Median or no. . | Range or percentage . |
|---|---|---|
| Peripheral blood | ||
| Neutrophils, ×109/L | 5.1 | 0-70.2 |
| Hemoglobin, g/dL | 10.1 | 7.1-15.4 |
| Platelets, ×109/L | 97.8 | 3-2420 |
| Blasts, % | 3 | 0-97 |
| Basophils, % | 4 | 0-70 |
| Bone marrow | ||
| Blasts, % | 15 | 0-96 |
| Basophils, % | 3 | 0-72 |
| Cytogenetics | ||
| Ph+, % | 100 | 7-100 |
| Clonal evolution | 113 | 77 |
| Chromosomal abnormalities in Ph− cells | 6 | 4 |
| BCR-ABL kinase domain point mutations | ||
| Yes | 52 | 36 |
| No | 54 | 37 |
| Not available | 40 | 27 |
| Duration of CML at start second/third TKI, mo | 63 | 4-220 |
| Stage at start of second/third TKI | ||
| Accelerated phase | 83 | 57 |
| Blast phase | 57 | 39 |
| Myeloid | 39 | 27 |
| Lymphoid | 13 | 9 |
| Extramedullary disease | 5 | 3 |
| Ph+ acute lymphoblastic leukemia | 6 | 4 |
| Type of second/third TKI | ||
| Dasatinib | 69 | 47 |
| Nilotinib | 77 | 53 |
| Characteristic . | Median or no. . | Range or percentage . |
|---|---|---|
| Peripheral blood | ||
| Neutrophils, ×109/L | 5.1 | 0-70.2 |
| Hemoglobin, g/dL | 10.1 | 7.1-15.4 |
| Platelets, ×109/L | 97.8 | 3-2420 |
| Blasts, % | 3 | 0-97 |
| Basophils, % | 4 | 0-70 |
| Bone marrow | ||
| Blasts, % | 15 | 0-96 |
| Basophils, % | 3 | 0-72 |
| Cytogenetics | ||
| Ph+, % | 100 | 7-100 |
| Clonal evolution | 113 | 77 |
| Chromosomal abnormalities in Ph− cells | 6 | 4 |
| BCR-ABL kinase domain point mutations | ||
| Yes | 52 | 36 |
| No | 54 | 37 |
| Not available | 40 | 27 |
| Duration of CML at start second/third TKI, mo | 63 | 4-220 |
| Stage at start of second/third TKI | ||
| Accelerated phase | 83 | 57 |
| Blast phase | 57 | 39 |
| Myeloid | 39 | 27 |
| Lymphoid | 13 | 9 |
| Extramedullary disease | 5 | 3 |
| Ph+ acute lymphoblastic leukemia | 6 | 4 |
| Type of second/third TKI | ||
| Dasatinib | 69 | 47 |
| Nilotinib | 77 | 53 |
Clonal evolution indicates the presence of additional chromosomal abnormalities in the Ph+ cells, excluding variant Ph translocations, a loss of chromosome Y, or constitutional abnormalities.